Amylin Pharmaceuticals Inc. (AMLN)

[surf1944]

7:03AM Amylin Pharms beats by $0.02, misses on revs (AMLN) 21.75 : Reports GAAP Q1 (Mar) loss of $0.27 per share, $0.02 better than the Thomson Reuters consensus of ($0.29); revenues fell 3.3% year/year to $174 mln vs the $187.8 mln consensus. Net product sales of $172.3 million for the quarter ended March 31, 2010 include $149.8 million for BYETTA (exenatide) injection and $22.5 million for SYMLIN (pramlintide acetate) injection. This compares to net product sales of $179.3 million, consisting of $157.7 million for BYETTA and $21.6 million for SYMLIN for the same period in 2009. BYDUREON response to FDA will be submitted this week BYDUREON marketing authorization application submitted to the european medicines agency. "With the submission of our BYDUREON response this week, we are preparing to make this revolutionary treatment option available this year to the millions of patients living with type 2 diabetes. We remain focused on driving revenue from our currently marketed products, BYETTA and SYMLIN, and continue to exercise financial discipline so that we remain on track to generate sustainable positive operating cash flow by year end."